Matt Hoffman

FDA's acting deputy commissioner for food said the US food supply remains safe even as CDC-confirmed cyclosporiasis cases climbed past 11,000, while a new survey found nearly half of Americans don't trust the agency to manage the outbreak.

Sharon Nachman, MD, chief of pediatric infectious disease at Stony Brook Children's Hospital, explains why local resistance data, not just global forecasts, should drive today's empiric antibiotic choices in children.

A global surveillance study of more than 100,000 pediatric bacterial isolates found rising antimicrobial resistance across all regions from 2004 to 2022, with forecasts projecting continued increases in resistance to last-line antibiotics through 2035.

A Rutgers Health study in Health Affairs found substantial growth in long-acting injectable buprenorphine prescriptions for opioid use disorder from 2021 to 2024, but with sharp state-level disparities driven by Medicaid policy differences, with fewer than 1% of buprenorphine prescribed as injectable in some states versus nearly 13% in others.

Shionogi's XOCOVA (ensitrelvir) is now available in the United States as the first oral option to help prevent COVID-19 after exposure, following phase 3 SCORPIO-PEP trial data showing a 67% reduction in symptomatic infection risk.

Three concurrent studies identify T cell exhaustion and Th2 skewing as distinct immune phenotypes in disseminated coccidioidomycosis, with targeted immunomodulation producing dramatic clinical responses in patients who had failed standard antifungal therapy.

ViiV Healthcare's 2-drug Dovato regimen met its noninferiority end point against Gilead's 3-drug Biktarvy in the first head-to-head randomized trial comparing the 2 in treatment-naive adults with HIV.

As the Cyclospora outbreak continues, clinicians and public health advocates are highlighting a secondary risk: antibiotic treatment for the parasitic infection can disrupt the gut microbiome and raise the risk of C diff.

A study of 87 free-roaming New York City cats found 57.5% harbored at least 1 zoonotic endoparasite, with young male cats identified as Toxocara super-shedders depositing disproportionately high concentrations of roundworm eggs into urban soil.

The US has confirmed more measles cases in 2026 than in any year since 1991, with CDC and Johns Hopkins trackers both surpassing 2025's full-year total 5 months before year's end.

CDC's confirmed case count for the Cyclospora outbreak linked to Taylor Farms de Mexico lettuce has topped 4000 as FDA opens a second, separate outbreak investigation and lawmakers press for restored FoodNet surveillance.

Basecamp Research's EDEN AI model, now integrated with Claude Science, designed antibiotic peptides active against 97% of WHO priority pathogens in lab tests, including MDR Acinetobacter baumannii, and can reduce vaccine target prioritization from weeks to a single AI conversation.

The FDA has granted EUA for the Allplex HSV-1&2/VZV/MPXV Assay (Seegene USA), the first multiplex PCR test designed to simultaneously differentiate HSV-1, HSV-2, VZV, and mpox virus from ulcerative skin lesions in a single run.

Phase 3 ISLEND-1 and ISLEND-2 trials showed once-weekly oral islatravir/lenacapavir was noninferior to daily BIKTARVY and standard of care ART in maintaining virologic suppression at Week 48, with no new safety concerns identified.

Merck has reached an agreement with the ADAP Crisis Task Force to help state AIDS Drug Assistance Programs provide doravirine/islatravir access to eligible, virologically suppressed people with HIV.

Four HIV Awareness Month conversations with Kristine Erlandson, MD; Joanne Stekler, MD, MPH; Oni Blackstock, MD, MHS; and Jason Baeten, MD, PhD, reveal what's holding back an epidemic we have the tools to end.

Jared Baeten, MD, PhD, discusses what the PURPOSE 1 and 2 trial data reveal about lenacapavir adherence, long-acting PrEP candidate selection, the treatment pipeline, and access barriers for twice-yearly injectable HIV prevention.

Oni Blackstock, MD, MHS, discusses why HIV prevention stalls despite breakthroughs: funding cuts, Medicaid gaps, and structural racism keep PrEP and care out of reach.

Invivyd has dosed the first participants in LIBERTY, a phase 3 trial comparing VYD2311 to an mRNA COVID vaccine and coadministration, as the BLA-enabling DECLARATION trial completes enrollment.

Joanne D. Stekler, MD, MPH, discusses why many Americans still miss HIV diagnosis—and how opt-out screening, rapid tests, self-tests, and same-day treatment close the gap.

Why people with HIV age faster: Kristine Erlandson, MD, offers expert tips on frailty, HAND screening, statins post-REPRIEVE, and avoiding ART drug interactions.

The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HDV with no prior treatment options.

A study assessing the local transmission found it caused 14 confirmed cases in 2024 and exposed diagnostic delays in patients without travel history.

The FDA’s biologics center faces another leadership shake-up as Vinay Prasad, MD, MPH, plans an exit in April, leaving questions over vaccine rules and gene-therapy approvals.

After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.

The official cause of death is still under investigation by the New Mexico Office of the Medical Investigator, though the individual tested positive for the measles virus.

A serious adverse event of motor neuropathy reported in September 2024 has resulted in a hold on the investigational new drug application.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.

The test was validated as part of the NIH’s RADx tech program through its Independent Test Assessment Program, in collaboration with the FDA.

A newly published study suggests that a 15-day regimen, while safe, did not statistically separate from a placebo comparator group in main outcomes for PASC of SARS-CoV-2 infection.